Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
This article was originally published in The Pink Sheet Daily
Executive Summary
Crucell would fit Wyeth’s ongoing effort to extend geographic base for vaccines and provide new candidates and technologies to provide depth to the company’s vaccine R&D effort.
You may also be interested in...
Emilio Emini Is The Key To Wyeth Vaccines
In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
Emilio Emini Is The Key To Wyeth Vaccines
In touting the $68 billion proposed deal for Wyeth, Pfizer CEO Jeff Kindler repeatedly cited Wyeth's vaccine business as a key part of the deal. But what exactly will Pfizer get after scooping up this unit? Two crucial assets - one is a product and the other is a person